Assesment effectiveness of treatment Eustachian tube dysfunction using pneumatic inhaler AMSA

Insights

Inhaler AMSA treatment significantly improved Eustachian tube dysfunction and conductive hearing loss in children more quickly than traditional pharmacotherapy.

Area of Science:

  • Otolaryngology
  • Pediatric Medicine
  • Audiology

Background:

  • Upper respiratory tract infections are common in children, increasing susceptibility to middle ear infections.
  • Children's Eustachian tube anatomy predisposes them to impaired patency and conductive hearing loss.
  • Eustachian tube dysfunction is a frequent complication of pediatric upper respiratory infections.

Purpose of the Study:

  • To assess the effectiveness of the AMSA inhaler for treating Eustachian tube dysfunction.
  • To compare AMSA inhaler treatment with conventional pharmacotherapy for Eustachian tube dysfunction.
  • To evaluate the impact of AMSA inhaler on conductive hearing loss associated with Eustachian tube dysfunction.

Main Methods:

  • A study group of 30 patients with conductive hearing loss was treated with the AMSA inhaler.
  • A control group of 30 patients received pharmacological treatment for Eustachian tube dysfunction.
  • Pure-tone audiometry and impedance testing were conducted at baseline, 1 week, and 4 weeks.

Main Results:

  • Patients treated with the AMSA inhaler showed statistically significant improvement in studied parameters.
  • Improvement in Eustachian tube dysfunction and hearing parameters occurred faster with AMSA inhaler treatment.
  • AMSA inhaler therapy demonstrated superior efficacy compared to pharmacotherapy in a shorter timeframe.

Conclusions:

  • The AMSA inhaler is an effective treatment for Eustachian tube dysfunction in children.
  • AMSA inhaler treatment offers a faster resolution of conductive hearing loss compared to pharmacotherapy.
  • This study supports the use of AMSA inhaler as a beneficial therapeutic option for pediatric Eustachian tube dysfunction.
Abstract